Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2022 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

GAITHERSBURG, Md., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety and immunogenicity of the company’s adjuvanted...
September 06, 2022 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and...
October 10, 2019 06:38 ET | Source: Emergent BioSolutions

Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate

GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate,...
April 16, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate

GAITHERSBURG, Md., April 16, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and...
August 16, 2018 06:15 ET | Source: Emergent BioSolutions

CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine

OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus...
August 16, 2018 06:15 ET | Source: Emergent Biosolutions, Inc.

CEPI vergibt Vertrag im Wert von bis zu 36 Mio. US-Dollar zur Entwicklung eines Impfstoffs gegen das Lassa-Virus an Profectus BioSciences und Emergent BioSolutions

OSLO, Norwegen, BALTIMORE und GAITHERSBURG, Maryland, USA, Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (die Coalition for Epidemic Preparedness Innovations) gab heute eine neue Kooperation mit Profectus...
August 13, 2018 11:59 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions übernimmt Spezialimpfstoffunternehmen PaxVax

Hinzufügung von zwei umsatzgenerierenden, von der FDA zugelassenen Impfstoffen, die gegen Cholera und Typhus schützen, beide mit dualem MarktpotenzialErweiterung der Entwicklungspipeline durch einen...
August 13, 2018 11:59 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax

Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potentialBroadens development pipeline with an adenovirus 4/7 vaccine funded by...
August 09, 2018 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax

Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potentialBroadens development pipeline with an adenovirus 4/7 vaccine funded by...